Physician profile
Danielle Beatty
NPI 1659811453
$7,149.78
in general payments reported to CMS, 2019-2025
59 companies · $2,235 in 2025
The $2,235 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $543 · 2022: $982 · 2023: $1,849 · 2024: $1,540 · 2025: $2,235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,624.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $551.15 | 2021-2025 | Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $476.84 | 2022-2025 | |
| Gilead Sciences, INC. | $380.03 | 2022-2025 | Trodelvy |
| Daiichi Sankyo INC. | $376.63 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Pfizer INC. | $343.78 | 2022-2025 | |
| Eisai INC. | $340.36 | 2021-2025 | |
| Janssen Biotech, INC. | $325.38 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Incyte Corporation | $323.78 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Astrazeneca Pharmaceuticals LP | $270.11 | 2021-2025 | Enhertu, Calquence |
| Astellas Pharma US INC | $265.60 | 2021-2025 | Xospata, Vyloy, Padcev |
| Merck Sharp & Dohme LLC | $251.24 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Abbvie INC. | $242.29 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $218.37 | 2023-2025 | Libtayo |
| Seagen INC. | $209.07 | 2021-2023 | Tukysa, Adcetris, Tivdak |
| Takeda Pharmaceuticals U.S.A., INC. | $150.93 | 2023-2025 | Alunbrig, Hyqvia, Fruzaqla |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $143.83 | 2023-2025 | Xpovio |
| Celgene Corporation | $140.31 | 2022-2025 | Pomalyst, Reblozyl |
| Tersera Therapeutics LLC | $124.11 | 2024-2025 | Zoladex |
| Puma Biotechnology, INC. | $117.43 | 2021-2025 | |
| Genzyme Corporation | $115.69 | 2022-2025 | |
| Array Biopharma INC | $114.85 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Amgen INC. | $112.62 | 2021-2023 | Lumakras |
| Lilly USA, LLC | $108.75 | 2021-2024 | Jaypirca, Verzenio, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $98.14 | 2021-2025 | |
| Aveo Pharmaceuticals, INC. | $95.06 | 2023-2025 | Fotivda |
| Exelixis INC. | $82.16 | 2023-2025 | Cabometyx |
| Sobi, INC | $80.45 | 2022-2025 | |
| Deciphera Pharmaceuticals INC. | $77.84 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $77.23 | 2021-2023 | |
| Glaxosmithkline, LLC. | $70.48 | 2023-2024 | Ojjaara, Jemperli, Zejula |
| Kite Pharma, INC. | $70.31 | 2023-2025 | Yescarta |
| Beigene USA, INC. | $48.74 | 2024 | Brukinsa |
| Pharmaessentia USA Corporation | $46.24 | 2023-2025 | Besremi |
| Taiho Oncology, INC. | $44.82 | 2022-2025 | |
| Tg Therapeutics, INC. | $43.22 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $41.37 | 2023 | Empaveli |
| Genmab U.S., INC. | $41.22 | 2024-2025 | Epkinly |
| Ipsen Biopharmaceuticals, INC | $40.51 | 2024-2025 | Somatuline Depot, Onivyde |
| Genentech USA, INC. | $40.18 | 2024 | Tecentriq, Polivy, Alecensa |
| Emd Serono, INC. | $38.19 | 2025 | |
| Pharmacosmos Therapeutics INC. | $37.62 | 2025 | Monoferric |
| Dendreon Pharmaceuticals LLC | $33.62 | 2023 | Provenge |
| Blueprint Medicines Corporation | $28.44 | 2025 | Ayvakit |
| Telix Pharmaceuticals | $24.57 | 2023 | Illuccix |
| Stemline Therapeutics INC. | $24.20 | 2023 | Orserdu |
| Pharmacyclics LLC, An Abbvie Company | $24.20 | 2023 | Imbruvica |
| Rigel Pharmaceuticals, INC. | $24.13 | 2023 | Tavalisse, Rezlidhia |
| Mirati Therapeutics, INC. | $21.99 | 2023 | Krazati |
| Heron Therapeutics, INC. | $21.32 | 2022 | |
| Alexion Pharmaceuticals, INC. | $20.92 | 2025 | Ultomiris |
| Ge Healthcare | $20.07 | 2022 | |
| Amag Pharmaceuticals, INC. | $19.51 | 2021 | |
| Agios Pharmaceuticals, INC. | $17.70 | 2025 | Pyrukynd |
| Morphosys, US INC. | $17.22 | 2023 | Monjuvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.25 | 2021 | |
| Myovant Sciences INC. | $15.74 | 2022 | |
| Sumitomo Pharma America, INC. | $15.13 | 2024 | Orgovyx |
| Beone Medicines USA, INC. | $14.12 | 2025 | Brukinsa |
| Acrotech Biopharma INC. | $13.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Beatty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.